Business
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2025 Financial Results
OLDSMAR, Fla., October 15, 2025--Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the "Company", "Cryo-Cell"), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2025.
About this update from Cryo-cell International, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/162764595d46c35dcad0b6aee4da1ca2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/w_4S_cqf.ex4CmdAdZ0W1A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/162764595d46c35dcad0b6aee4da1ca2","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/6hrdakzy6AQbbFok7KKjOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/162764595d46c35dcad0b6aee4da1ca2","width":1024,"height":512}},"lazy":false},{"type":"text","content":"OLDSMAR, Fla., October 15, 2025--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the "Company", "Cryo-Cell"), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2025.","length":316,"tagName":"p"},{"type":"text","content":"Financial Results","length":17,"tagName":"p"},{"type":"text","content":"Revenue","length":7,"tagName":"p"},{"type":"text","content":"Consolidated revenues for the third quarter of fiscal 2025 were $7.83 million compared to $8.07 million for the third quarter of fiscal 2024, a 3% decrease.","length":156,"tagName":"p"},{"type":"text","content":"Net Income","length":10,"tagName":"p"},{"type":"text","content":"The Company reported net income for the three months ended August 31, 2025 of $749,000, or $0.09 per basic share and diluted share, compared to net income of $1.05 million, or $0.13 per basic and diluted share for the three months ended August 31, 2024.","length":253,"tagName":"p"},{"type":"text","content":"About Cryo-Cell International, Inc.","length":35,"tagName":"p"},{"type":"text","content":"Founded in 1989, Cryo-Cell International, Inc. is the world’s first private cord blood bank. More than 500,000 parents from 87 countries have entrusted Cryo-Cell International, Inc. with their baby’s cord blood and cord tissue stem cells. In addition to its private bank, Cryo-Cell International, Inc. has a public banking program in partnership with Duke University. Cryo-Cell’s public bank has provided cord blood for more than 700 transpl...